Martin H Bolli

Summary

Affiliation: Actelion Pharmaceuticals Ltd
Country: Switzerland

Publications

  1. ncbi Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls
    Martin H Bolli
    Drug Discovery Chemistry, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Curr Top Med Chem 11:726-57. 2011
  2. ncbi The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
    Martin H Bolli
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil BL, Switzerland
    Bioorg Med Chem Lett 13:955-9. 2003
  3. ncbi Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists
    Martin H Bolli
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    J Med Chem 47:2776-95. 2004
  4. ncbi 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists
    Martin H Bolli
    Drug Discovery Chemistry, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Med Chem 53:4198-211. 2010
  5. ncbi Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
    Marc Iglarz
    Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Pharmacol Exp Ther 327:736-45. 2008
  6. ncbi Bis-sulfonamides as endothelin receptor antagonists
    Christoph Boss
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil BL, Switzerland
    Bioorg Med Chem Lett 13:951-4. 2003
  7. ncbi The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation
    Luca Piali
    Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland
    J Pharmacol Exp Ther 337:547-56. 2011

Collaborators

Detail Information

Publications7

  1. ncbi Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls
    Martin H Bolli
    Drug Discovery Chemistry, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Curr Top Med Chem 11:726-57. 2011
    ..In particular, the complexity of discovering a molecule akin to FTY720 but with an improved side-effect profile will be discussed...
  2. ncbi The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
    Martin H Bolli
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil BL, Switzerland
    Bioorg Med Chem Lett 13:955-9. 2003
    ..g., 70 and 75). The propargyl derivative 26 significantly reduced blood pressure in in vivo model studies with hypertensive salt-sensitive Dahl rats...
  3. ncbi Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists
    Martin H Bolli
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    J Med Chem 47:2776-95. 2004
    ..In this animal model, the efficacy of the benzo[e][1,4]diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2...
  4. ncbi 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists
    Martin H Bolli
    Drug Discovery Chemistry, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Med Chem 53:4198-211. 2010
    ..At a dose of 100 mg/kg, the effect on lymphocyte counts was fully reversible within less than 36 h. Pharmacokinetic investigation of 8bo in beagle dogs suggests that the compound is suitable for once daily dosing in humans...
  5. ncbi Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
    Marc Iglarz
    Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Pharmacol Exp Ther 327:736-45. 2008
    ..This profile makes macitentan a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation...
  6. ncbi Bis-sulfonamides as endothelin receptor antagonists
    Christoph Boss
    Drug Discovery Chemistry and Preclinical Research, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil BL, Switzerland
    Bioorg Med Chem Lett 13:951-4. 2003
    ..This allowed to prepare dual ET(A)/ET(B) as well as ET(B) receptor selective antagonists, which could serve as tools to investigate the pharmacological consequences of selective ET(B) receptor blockade...
  7. ncbi The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation
    Luca Piali
    Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland
    J Pharmacol Exp Ther 337:547-56. 2011
    ..Immunomodulation with a rapidly reversible S1P(1)-selective agonist may represent a new therapeutic approach in lymphocyte-mediated autoimmune diseases...